

## Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

In this article (Clin Cancer Res 2014;20:5908–17), which was published in the December 1, 2014, issue of *Clinical Cancer Research* (1), one of the authors' names was misprinted. The corrected name should read as follows: "Aurelius Omlin." The publisher regrets this error.

### Reference

1. Blagden S, Omlin A, Josephs D, Stavraka C, Zivi A, Pinato DJ, et al. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin Cancer Res 2014;20:5908–17.

---

Published online February 2, 2015.  
doi: 10.1158/1078-0432.CCR-14-3188  
©2015 American Association for Cancer Research.